ERYP vs. HUMA, ALLO, CMPX, AURA, TECX, GLUE, TSHA, PROK, TRML, and RGNX
Should you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Humacyte (HUMA), Allogene Therapeutics (ALLO), Compass Therapeutics (CMPX), Aura Biosciences (AURA), Tectonic Therapeutic (TECX), Monte Rosa Therapeutics (GLUE), Taysha Gene Therapies (TSHA), ProKidney (PROK), Tourmaline Bio (TRML), and REGENXBIO (RGNX). These companies are all part of the "biological products, except diagnostic" industry.
ERYTECH Pharma vs.
ERYTECH Pharma (NASDAQ:ERYP) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking.
In the previous week, Humacyte had 13 more articles in the media than ERYTECH Pharma. MarketBeat recorded 13 mentions for Humacyte and 0 mentions for ERYTECH Pharma. Humacyte's average media sentiment score of 0.17 beat ERYTECH Pharma's score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.
ERYTECH Pharma has a beta of 2.69, indicating that its share price is 169% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500.
Humacyte has a consensus price target of $13.71, indicating a potential upside of 358.67%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than ERYTECH Pharma.
ERYTECH Pharma received 123 more outperform votes than Humacyte when rated by MarketBeat users. However, 69.64% of users gave Humacyte an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote.
ERYTECH Pharma has higher revenue and earnings than Humacyte.
ERYTECH Pharma's return on equity of 0.00% beat Humacyte's return on equity.
1.1% of ERYTECH Pharma shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 1.9% of ERYTECH Pharma shares are owned by insiders. Comparatively, 11.2% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Humacyte beats ERYTECH Pharma on 10 of the 16 factors compared between the two stocks.
Get ERYTECH Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ERYTECH Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:ERYP) was last updated on 3/12/2025 by MarketBeat.com Staff
